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Fibrin sealant, aprotinin, and immune response in
children undergoing operations for congenital heart
disease
To the Editor:
In their well-planned study of 49 children, "Fibrin Sealant.
Aprotinin. and Immune Response m Children Undergoing
Operations for Congenital Heart Disease" (1 Thorac Cardio-
vasc Surg 1998;1 15:883-9). Scheule and colleagues advise
the reader that antibovine antIbodies can be formed after pro-
fessional application of a fibrin sealant. It is interesting to
note that only some of the patients formed antIbodies (14'7c
Immunoglobulm fIg] E antibodies. 399c IgG antIbodies);
most patients did not form antibodies against aprotmin after
identical application of the fibrIn sealant.
Here it is important to ask the follOWIng question: Which
factors led to the increm,ed antIbody formation? Even if data
m Table IV do not show a significant difference with respect
to the dose of aprotinin and the age of patients. the higher
dose of aprotinin used in the older children seems to lead to
an increased Incidence of IgE or IgG antibodies. We must not
forget that children of this age receive bovine milk products
with their food. The gastrointestinal tract cannot be consid-
ered an absolute barner for nutritious proteins. which can to
some degree get into the blood wIthout being degraded, and
thus previous sensItization against bovine proteins cannot be
excluded. A test for antibovine protein at baseline would have
answered thIS question. We consider thIS a serious shortcom-
ing of the study design that makes the conclusion doubtful.
Scheule and colleagues claSSIfied only the specific TgE
antIbodie, according to their quantIty, and only m I case
could the level be classified as "high" (class III radio-aller-
gosorbence test/tluorescence enzyme immunoassay). In this
case the high value had already been determmed I week after
aprotinin application. which lead, us to conclude that thIS
patient had been sensitized against bovine protein before and
that aprotinin in the fibrin sealant led to a booster effect.
The next important questIOn IS the clinical relevance of the
antibodies found. ScheuIe and colleagues show that IgE anti-
body disappeared I year after exposure, suggesting a short
half-life and therefore a low clinical relevance if any.
As far as we know from the manufacturer's pharmacovigi-
lance department. there have only been :2 reports of anaphy-
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lactic reactIOns. In both cases the patients responded to stan-
dard treatment. The reports represent 2 cases in approximate-
ly 5 mIllion applications, yielding a rate of 1 in 2,5 million.
To mInimize any risk, the medIcal histories taken before an
operation should include questions on known allergies of any
type and prevIous application of aprotinin. which may be
used predominantly m heart surgery.
G. Schlag, MD
Professor ofAnaesthesio!ogy












Reply to the Editor:
We appreciate the interest of Drs Schlag and Seifert in the
outcome of our studyl and feel confirmed in our view
because they also conclude that the risk of allergic reactions
to aprotinin should be minimized. In our study we proved that
there is an Immune response to even locally applied apro-
tinin. as contamed in commercially available fibrin sealant.
The question of the pathophysiologic and clinical signifi-
cance of thIS immune response, however. arIses consistently.
More important than the measurable quantity is the quality of
the immune response. The pathophysiologic effect of aller-
gen-specific antIbodies relies more on mast cell-bound
immunoglobulin (Ig) E than on high serum levels. Bovine
milk products probably do not influence antIbody formation
to any great extent. as contended hy Schlag and Seifert 8 of
our patients received a dIet free of cow's milk for medical or
ideologic reasons. and 7 of them were even not breast-fed.
Nevertheless. aprotimn-specific IgG was found in 3 of these
patients and aprotinin-specific IgE was found m I. We do not
thmk that a test for antibovme protein at baselme would have
furnIshed further clarification than did the measurement of
total serum TgG and TgE concentrations. There is no meaning
in examining the serum before exposure with a non~pecific
global test when it is possible to apply a test specific for
serum antibodies against a well-known and circumscribed
Immunogenic epitope of a protem originating in bovine lung
tissue. On this point we clearly dIsagree with Schlag and
Seifert. Rather. we consider this approach a highlight of our
study design that made our conclusions more convincing.
Of course it cannot be ruled out that consumption of bovine
proteins may senSItize patients to aprotmin. This may explain
shock. reactions without former exposure to aprotmin. To
date, however. thIS sensitIzing mechamsm has only been
observed in the opposite directIOn. namely from aprotinm to
other bovine proteins. 2 Our patient classified a~ having a
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highly positive result for IgE at I week had a tracheal steno-
sis from pulmonary artery sling syndrome and had prevIOus-
ly been operated on in another institution, without document-
ed use of fibrin tissue adhesive. The preoperative serum
sample yielded negatIve results for both IgG and IgE.
Because full immunocompetence matures only within the
first years after bIrth. age seems to be a more important and
physiologic factor. This mfluence, however. was not :,ignifi-
cant in our study because the number of patients was too
small.
As far as clmical relevance of a positive antibody status is
concerned. our observation of rapidly di:,appearing IgE levels
fIts perfectly with observatIOns m mo:,t case reports III which
anaphylactic reactions to intravenous reexpo:,ure to aprotinin
occurred within a few months after primary exposure. Taking
into account the similarities of the immune responses to local
and intravenous aprotinin. we conclude that the risk of aller-
gy i:, highest in the early postoperatl\'e penod. extendlllg for
:,neral weeks. We are aware of ..( anaphylactic reaclion:,
caused by the aprotmlll component of fibrin tis:-.ue adhesive:,;
3 cases have been pubhshed3-5 and another (unpubhshed
data) occurred in a neurosurgical patient reexposed within a
few weeks. Three of these patients had IgE demonstrated: the
fourth had positive results of histamine release and lympho-
cyte transformation tests. Fortunately, all patients responded
to standard antiallergic treatment.
We agree with Schlag and SeIfert that a precise medical
history obtallled before the operation is crucial to milllmize
the risk of allergic reaction. Unfortunately. known allergies of
any type are not prognostically helpfuL as our recent study of
150 adult patients revealed: the incidence of aprotillln-specif-
ic IgG was the same among patients with and without histo-
ry of allergy.6 Yet our mo:,t recent study examilllng preopera-
tive serum samples from 520 cardiac surgical patients
indicates that a history of previous operations in di:,ciplines
with frequent use of intravenous aprotinin or tissue sealants
(eg, cardiovascular surgery and otorhinolaryngology) per-
formed not long before the mdex exposure may have a pre-
dictive power for antiaprotinin seropositivity.7
We conclude that allergic reaction, to the aprotinin compo-
nent of commercially aVailable fibrin tissue adhesives are
extremely rare. but for patients with recent aprotinin contact
III any form this risk is clilllcally relevant and has to be taken
into account before reexpo<;ure.
G. Ziemer, MD, PhD
A. M. Scheu Ie. MD
Division ofTlwracic. Cardiac. and Vl:lScular Surger\'
Department of Surgery
Tiibingen University Hospital
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Surgical implications of platelet glycoprotein IIb-
lIla inhibition
To the Editor:
We read with interest the brief communication by Alvarez l
regarding his experience with 3 patients undergoing emer-
gency coronary artery bypass grafting after platelet glycopro-
tein (Gp) Ilb-IlIa inhihition. We aIso have observed excessive
mediastmal bleedmg and increa:,ed transfw,ion requirement~
when operating on patients exposed to the GpIIb-IlIa
inhibitor abcixlmab.c Although the use of these potent
mhibltors of platelet aggregation is a major breakthrough m
the treatment of acute coronary syndromes. it is becommg
clear that operating on patient:, with actIve GplIb-IlIa mhibl-
lion represent~ a major challenge for the surgeon and a ~lg­
mticant risk. for the patient.
In our smalL retrospective series. we noted that the interval
from cessation of abciximab administration to operation was
critical m determming the degree of coagulopathy after the
operation. Patients who underwent an emergency operation
within 12 hours of admmistration had :,igniticantly greater
transfusion requirements and bleeding than did patients for
whom the operatIOn could be delayed longer than 12 hours.
ThIS clmical observation correlates WIth pharmacodynamic
studie:, of abciximab. which demon,trate a half-life of
approximately 12 hours. Platelet aggregation tS severely dys-
functIOnal in patients operated on withm thIS penod.
Optimal management of patient, undergoing emergency
cardiac operations after GpIlb-IlIa inhIbition is evolving. We
believe that there are 3 critical components for the surgical
management of these patients: (I) transfusion therapy. (2)
reduced heparinizatIOn. and (3) delay of surgical interventIon
when possible until after clearance of the inhtbitor.
Transfusion therapy with pooled platelets IS essentIal to
mcrease the number of functional platelets. Abci",imab i" ..J
chlmenc human-munne monoclonal antibody fragment that
